Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 2023
ClinicalTrials.gov · Datasets · License: Public Domain · 2023
Open Source ↗
targeted-therapy
early-stage breast cancer, her2-positive breast cancer, adjuvant treatment after trastuzumab, rcb classification 1-2, neratini, hormone receptor positive her2 positive breast cancer, targeted therapy, adjuvant therapy, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 891617
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.